<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Retinoblastoma: Treatment and outcome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Retinoblastoma: Treatment and outcome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Retinoblastoma: Treatment and outcome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jesse L Berry, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evelyn A Paysse, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4063193209">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinoblastoma is the most common primary intraocular malignancy of childhood and accounts for 10 to 15 percent of cancers within the first year of life [
         <a href="#rid1">
          1
         </a>
         ]. Retinoblastoma typically presents as leukocoria  (
         <a class="graphic graphic_picture graphicRef56724" href="/z/d/graphic/56724.html" rel="external">
          picture 1
         </a>
         ) in a child under the age of two years. Untreated retinoblastoma is a deadly disease; however, with advances in treatment, survival in the contemporary era is &gt;95 percent. Prompt referral to an ocular oncologist and appropriate management by a multidisciplinary team are necessary to optimize visual outcome and ocular and overall survival.
        </p>
        <p>
         The clinical treatment and outcome of retinoblastoma are reviewed here. The clinical presentation, evaluation, and diagnosis of retinoblastoma and the approach to children with leukocoria are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6259.html" rel="external">
          "Approach to the child with leukocoria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3658557994">
         <span class="h1">
          MULTIDISCIPLINARY APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of children with retinoblastoma is best accomplished by a multidisciplinary team, which can consolidate clinic visits and provide the caregivers with opportunities to discuss the full spectrum of treatment and outcomes. The multidisciplinary team may include the following health care professionals:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pediatric ophthalmologist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary care practitioner
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pediatric oncologist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation oncologist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical geneticist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retina specialist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ocular oncologist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroradiologist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Craniofacial plastic specialist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nurse specialist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Child life specialist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical social worker
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-vision specialist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ocularist
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nutritionist
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3323604168">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1475564894">
         <span class="h2">
          Goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of retinoblastoma is aimed at achieving the following goals [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eradication of the disease to prevent mortality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Salvage of the eye, if done without risk to the child's life
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preservation of vision to the greatest extent possible
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of late sequelae, particularly subsequent neoplasms (see
         <a class="local">
          'Second malignancies'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H190419708">
         <span class="h2">
          Treatment approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of treatment options are available for children with retinoblastoma, including several globe- and vision-sparing therapies [
         <a href="#rid3">
          3-5
         </a>
         ]. First-line therapeutic options include ophthalmic artery chemosurgery (OAC), systemic chemotherapy, radioactive plaques (I-125 brachytherapy), and enucleation. Adjunctive salvage therapies include cryotherapy, laser photoablation, and intravitreal injection of chemotherapy. In the contemporary era, external beam radiation therapy (EBRT) is rarely used, except in certain salvage situations.
        </p>
        <p>
         The choice of initial treatment is based on the tumor size, location, and laterality; presence or absence of vitreous or subretinal seeds; patient age; and visual prognosis. Group classification systems that evaluate the extent of disease in the eye, including the International Intraocular Retinoblastoma Classification and the American Joint Committee on Cancer 8
         <sup>
          th
         </sup>
         edition TNM, are commonly used to characterize the extent of disease and assess the likelihood of globe salvage  (
         <a class="graphic graphic_table graphicRef78948" href="/z/d/graphic/78948.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef131193" href="/z/d/graphic/131193.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3,6,7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Classification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H576023845">
         <span class="h3">
          Initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment options for initial therapy in children with newly diagnosed retinoblastoma are as follows  (
         <a class="graphic graphic_algorithm graphicRef108702" href="/z/d/graphic/108702.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="headingAnchor" id="H696812429">
         <span class="h4">
          Low-risk tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with unilateral or bilateral small extrafoveal tumors without subretinal or vitreous seeding (ie, group A and B tumors, particularly peripheral group B tumors)  (
         <a class="graphic graphic_table graphicRef78948" href="/z/d/graphic/78948.html" rel="external">
          table 1
         </a>
         ) can be managed with focal techniques, including cryotherapy or laser photocoagulation or (less commonly) plaque radiation therapy. (See
         <a class="local">
          'Cryotherapy and laser photocoagulation'
         </a>
         below.)
        </p>
        <p>
         In patients with tumors that involve the macula, laser photocoagulation and cryotherapy compromise central vision and, therefore, OAC or systemic intravenous chemotherapy is typically used to shrink the tumor before performing focal therapy. (See
         <a class="local">
          'Chemotherapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3925514329">
         <span class="h4">
          Moderate- and high-risk tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of advanced intraocular retinoblastoma is tailored according to the tumor burden with the aim of globe salvage if possible:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral group C and D tumors
         </strong>
         – Unilateral group C and many group D tumors  (
         <a class="graphic graphic_table graphicRef78948" href="/z/d/graphic/78948.html" rel="external">
          table 1
         </a>
         ) are treated with OAC or intravenous chemotherapy depending on the practice patterns of the center. Enucleation may be required for some group D tumors, particularly when the patient is young and presents with unilateral disease. For young infants (ie, &lt;3 months), single-agent systemic chemotherapy may be used as "bridge therapy" to provide time for the infant to grow to a size (typically &gt;6 or 7 kg) that permits successful arterial cannulation, at which time, OAC can be performed. (See
         <a class="local">
          'Chemotherapy'
         </a>
         below and
         <a class="local">
          'Enucleation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unilateral group E tumors
         </strong>
         – Children with unilateral group E tumors  (
         <a class="graphic graphic_table graphicRef78948" href="/z/d/graphic/78948.html" rel="external">
          table 1
         </a>
         ) are treated with enucleation. Adjuvant chemotherapy and radiotherapy are provided following enucleation if there are microscopic residua at the cut section of the optic nerve or sclera or if there are other high-risk pathologic features. (See
         <a class="local">
          'Enucleation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilateral disease
         </strong>
         – For patients with bilateral disease in which advanced stage tumor (ie, group C, D, or E)  (
         <a class="graphic graphic_table graphicRef78948" href="/z/d/graphic/78948.html" rel="external">
          table 1
         </a>
         ) is present in one or both eyes, treatment options may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal treatment (eg, laser photocoagulation, cryotherapy) for the least affected eye if the tumor is small and extrafoveal with enucleation of the more advanced eye. The child may require adjuvant chemotherapy if there are pathologic risk factors for the more advanced eye. (See
         <a class="local">
          'Cryotherapy and laser photocoagulation'
         </a>
         below and
         <a class="local">
          'Enucleation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic intravenous chemotherapy augmented by other consolidative therapies (laser, cryotherapy, brachytherapy, intravitreous chemotherapy). (See
         <a class="local">
          'Systemic chemotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bilateral OAC with or without intravitreous chemotherapy or other consolidative therapies. (See
         <a class="local">
          'Local chemotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with bilateral advanced disease, if one eye is primarily enucleated, systemic or local chemotherapy can be used in attempt to salvage the second eye. When salvage of both eyes is attempted, systemic intravenous chemotherapy or simultaneous (tandem) OAC to both eyes may be used as primary therapy [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2112240062">
         <span class="h4">
          Intracranial tumor ("trilateral" retinoblastoma)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trilateral retinoblastoma consists of unilateral or bilateral retinoblastoma associated with an intracranial tumor that is histologically similar but anatomically distinct  (
         <a class="graphic graphic_diagnosticimage graphicRef98797" href="/z/d/graphic/98797.html" rel="external">
          image 1
         </a>
         ). It is not metastatic nor from local spread but rather a separate primary tumor. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Intracranial tumors ("trilateral" retinoblastoma)'
         </a>
         .)
        </p>
        <p>
         Historically, treatment for patients with trilateral retinoblastoma has been neurosurgical resection followed by chemotherapy and cranial or craniospinal radiation therapy. Despite aggressive therapy, trilateral retinoblastoma was usually fatal [
         <a href="#rid5">
          5,9,10
         </a>
         ]. The use of intensive chemotherapy regimens combined with autologous hematopoietic stem cell rescue has been associated with prolonged disease-free survival in case series [
         <a href="#rid11">
          11-13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2942717260">
         <span class="h4">
          Metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastatic disease, though rarely present at the time of diagnosis, is associated with a poor prognosis. Intensive multimodal therapy (including high-dose multiagent chemotherapy and radiotherapy to bulky sites) with autologous hematopoietic stem cell rescue is used in some centers for treatment of metastatic disease [
         <a href="#rid3">
          3
         </a>
         ]. Based on several case series and one prospective study, the reported three- to five-year event-free survival is 60 to 80 percent with this approach [
         <a href="#rid14">
          14-18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Metastatic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2424520749">
         <span class="h3">
          Treatment failure and recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent intraocular disease is common in retinoblastoma. Many treatment failures or recurrences can be treated with repeat laser photocoagulation, cryotherapy, plaque brachytherapy, or intravitreal chemotherapy, depending on the size, location, and previous treatment history. However, larger recurrences may require OAC or further cycles of systemic chemotherapy for eye salvage [
         <a href="#rid19">
          19
         </a>
         ]. For large recurrences wherein the visual prognosis is poor, secondary enucleation is usually required to prevent spread of disease to sites outside the eye. Many centers use OAC with intravitreous chemotherapy if there is seeding for treatment of group D tumors that fail initial systemic chemotherapy. Reported globe salvage rates with this strategy are &gt;70 percent [
         <a href="#rid3">
          3,20
         </a>
         ].
        </p>
        <p>
         There are no reliable molecular biomarkers to predict which eyes will respond well to chemotherapy versus those that are more likely to fail therapy and relapse. However, work in this area, which often uses a "liquid biopsy" approach (ie, molecular testing performed on a blood sample and/or aqueous humor rather than a histopathologic specimen), is ongoing [
         <a href="#rid21">
          21-23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Disease extent'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H136152646">
         <span class="h2">
          Treatment modalities for intraocular disease
         </span>
        </p>
        <p class="headingAnchor" id="H210389462">
         <span class="h3">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The high risk of secondary radiation-induced cancers in patients with retinoblastoma has led to efforts to replace radiation therapy with either intravenous chemotherapy (popularized in the late 1980s) or OAC (popularized in the mid-2000s) combined with local consolidative measures, such as cryotherapy, laser photocoagulation, or local intravitreal injection of chemotherapeutic agents.
        </p>
        <p>
         Retinoblastoma is a chemotherapy-sensitive malignancy. The agents used most commonly for OAC include
         <a class="drug drug_pediatric" data-topicid="12579" href="/z/d/drug information/12579.html" rel="external">
          melphalan
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13005" href="/z/d/drug information/13005.html" rel="external">
          topotecan
         </a>
         ; various regimens are used for systemic therapy, most typically carboplatin,
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         , and topotecan [
         <a href="#rid4">
          4,24-26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3634122799">
         <span class="h4">
          Local chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of larger tumors is evolving with the development of ophthalmic artery (also known as intraarterial) chemotherapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intraarterial chemotherapy
         </strong>
         – In an effort to decrease systemic side effects and deliver high-dose, localized chemotherapy to the tumor, OAC was pioneered [
         <a href="#rid4">
          4,27,28
         </a>
         ]. This procedure is performed by a neuro- or endovascular surgeon. A cannula is introduced through the femoral artery and advanced to the ostium of the ophthalmic artery. Chemotherapy (typically
         <a class="drug drug_pediatric" data-topicid="12579" href="/z/d/drug information/12579.html" rel="external">
          melphalan
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         , and/or
         <a class="drug drug_pediatric" data-topicid="13005" href="/z/d/drug information/13005.html" rel="external">
          topotecan
         </a>
         ) is then delivered into the ophthalmic artery over approximately 30 minutes in a pulsatile fashion. The procedure is performed under general anesthesia, and nasal decongestant (vasoconstrictor) is typically sprayed in the nostril on the treatment side to shunt the blood away from the nasal mucosa in attempt to reduce local side effects [
         <a href="#rid4">
          4
         </a>
         ]. Successful OAC requires a high degree of specialized surgical skill, and it should be performed at centers experienced in this procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Indications and treatment protocols for OAC vary considerably between centers. There are no prospective trials comparing OAC with other treatment modalities in patients with retinoblastoma. It is generally believed that compared with systemic chemotherapy, which rarely cures intraocular retinoblastoma by itself, OAC may achieve higher drug levels in the eye and therefore theoretically has the potential to increase cure rates for advanced disease. It is important to note, however, that systemic chemotherapy is typically combined with local consolidative techniques (cryotherapy, photocoagulation, intravitreal injection of chemotherapy), which improves cure rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evidence for the efficacy and safety of OAC comes largely from case series [
         <a href="#rid29">
          29-36
         </a>
         ]. In a systematic review and meta-analysis that included 12 case series reporting outcomes in 655 patients (747 eyes) treated with OAC, globe salvage was achieved in 66 percent overall [
         <a href="#rid37">
          37
         </a>
         ]. The globe salvage rate was 86 percent in eyes with less advanced disease (ie, groups A, B, and C) compared with 57 percent in advanced disease (ie, groups D and E). Primary treatment with OAC was associated with a globe salvage rate of 74 percent, whereas the salvage rate was 67 percent in eyes where OAC was used as secondary treatment after failure of other modalities. Metastatic disease developed in 2.1 percent of patients treated with OAC in the published series; however, through author correspondence and a social media survey, the authors of the systematic review identified nine additional patients with metastases. Secondary malignant neoplasm occurred in 2.4 percent of patients, all of whom also received EBRT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Overall, there is a procedural learning curve to OAC, with higher rates of complications in the initial reports of OAC; however, with experience, complication rates are low (&lt;5 percent) in later reports [
         <a href="#rid3">
          3,36
         </a>
         ]. Local adverse effects of intraarterial chemotherapy may include eyelid edema; ptosis; loss of eyelashes; extraocular muscle dysfunction; delayed vitreous hemorrhage; potential blindness from stenosis or occlusion of the ophthalmic artery, central retinal artery, or branch retinal artery; chorioretinal atrophy; vasculopathy in ophthalmic, choroidal, and retinal vessels; and radiation exposure (from fluoroscopy). Systemic side effects include iodine allergy, risk for ischemia and hemorrhagic stroke, and bone marrow suppression [
         <a href="#rid27">
          27,28,37-42
         </a>
         ]. In addition, adverse autonomic cardiorespiratory reactions (bronchospasm) may occur [
         <a href="#rid28">
          28,37,43,44
         </a>
         ]. A pilot study from the Children's Oncology Group designed to study the feasibility of OAC with
         <a class="drug drug_pediatric" data-topicid="12579" href="/z/d/drug information/12579.html" rel="external">
          melphalan
         </a>
         for the treatment of unilateral group D disease was closed early due to multiple adverse events, most of which were post-procedural cardiorespiratory complications (bronchospasm) caused by cannulation of the internal carotid artery [
         <a href="#rid45">
          45
         </a>
         ]. As these events had not been well detailed in previous published reports, they were not anticipated in the study planning and, ultimately, this led to early closure of the study. Thus, the impact of OAC on globe salvage could not be evaluated. To date, there still remains no head-to-head prospective trial on the efficacy of OAC versus systemic chemotherapy and other consolidative therapies like intravitreal chemotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the systematic review described above, the most commonly reported ocular complications were periorbital edema or inflammation (66 of 196 eyes; 33 percent), retinal detachment (11 of 57 eyes; 19 percent), vitreous hemorrhage (30 of 166 eyes; 18 percent), ptosis (24 of 177 eyes; 14 percent), loss of eyelashes (14 of 134 eyes; 10 percent), dysmotility in (10 of 154 eyes; 6 percent), and vascular, ischemic, or atrophic effects (45 of 725 eyes; 6 percent) [
         <a href="#rid37">
          37
         </a>
         ]. Systemic complications were rare, and there were no reported episodes of stroke or neurologic complications. However, stroke has been reported in a single case report [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Systemic and local side effects may be under-reported due to lack of protocol-driven monitoring and/or follow-up for patients who were included in the available case series.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravitreous chemotherapy
         </strong>
         – Intravitreal chemotherapy is commonly used in conjunction with OAC or systemic chemotherapy for treatment of recurrent or refractory vitreous seeds, and in this setting, it has a success rate that approaches 100 percent [
         <a href="#rid3">
          3
         </a>
         ]. Historically, its use was limited due to concerns for potential tumor dissemination following intravitreal penetration; however, safety enhancing techniques (eg, use of small volume doses, lowering intraocular pressure prior to the injection with a paracentesis, treating the injection site with cryotherapy, irrigating the surface of the eye) have essentially eliminated any risk of tumor spread. In a 2013 systematic review of 14 studies (including &gt;1300 intravitreal injections), only a single reported case of extraocular tumor spread was identified [
         <a href="#rid47">
          47
         </a>
         ]. The optimal dose and potential toxicity of this treatment modality have yet to be fully elucidated; however, it has been exceedingly successful in the treatment of vitreous seeding and moreover, the avoidance of EBRT in these at-risk children. An ongoing clinical trial is evaluating the impact of intravitreal chemotherapy added to systemic chemotherapy on globe salvage in patients with persistent vitreous seeds [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Periocular injections
         </strong>
         – Sub-Tenon
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         was previously utilized as an adjunctive treatment with chemoreduction for groups C, D, and E tumors [
         <a href="#rid49">
          49-51
         </a>
         ]. However, this approach is limited by the risks of local side effects, which include orbital fat atrophy, motility limitation due to orbital scarring, orbital fat necrosis, and rarely, optic nerve atrophy [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1132514049">
         <span class="h4">
          Systemic chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic chemotherapy may be used in the following circumstances [
         <a href="#rid3">
          3,55-57
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with smaller tumors that impinge on the fovea to shrink the tumor before performing focal therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with large tumors and bilateral disease, for globe salvage and to shrink tumors that are too large for isolated local therapy (so-called "chemoreduction")
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In young infants (ie, &lt;3 months), as a "bridge therapy" to provide time for the infant to grow to a size that permits successful arterial cannulation for OAC (see
         <a class="local">
          'Local chemotherapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For adjuvant treatment after enucleation in patients at high risk for metastatic disease (ie, microscopic residua at the cut section of the optic nerve or sclera, or if there are other pathologic risk factors) (see
         <a class="local">
          'Enucleation'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of trilateral retinoblastoma and metastatic disease (see
         <a class="local">
          'Intracranial tumor ("trilateral" retinoblastoma)'
         </a>
         above and
         <a class="local">
          'Metastatic disease'
         </a>
         above)
        </p>
        <p>
        </p>
        <p>
         Since most retinoblastomas are large at the time of presentation, chemoreduction may be used to reduce tumor volume, which enhances the success of local therapies. Chemoreduction has become a critical component of the initial treatment of retinoblastoma and has improved the ocular salvage rate [
         <a href="#rid24">
          24,58-63
         </a>
         ]. The most common chemoreduction regimen contains
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12882" href="/z/d/drug information/12882.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         given approximately every 28 days for three to six cycles (depending on group classification). Alternatively, a topotecan-containing regimen has also proven to be effective in treatment of naïve patients [
         <a href="#rid26">
          26
         </a>
         ]. Other agents used include
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">
          doxorubicin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13373" href="/z/d/drug information/13373.html" rel="external">
          ifosfamide
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         In a retrospective report of 249 consecutive eyes treated with chemoreduction, treatment success (defined as avoidance of EBRT or enucleation) was achieved in 100 percent of group A, 93 percent of group B, 90 percent of group C, and 47 percent of group D eyes [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Chemoreduction is generally not an effective therapy for group E retinoblastoma, and the general recommendation for these tumors is enucleation, particularly if unilateral. For patients with bilateral high-grade tumors, systemic chemoreduction may be used (with or without other modalities such as low-dose EBRT) for ocular salvage [
         <a href="#rid62">
          62,63,66
         </a>
         ]. (See
         <a class="local">
          'Enucleation'
         </a>
         below.)
        </p>
        <p>
         Chemoreduction may also protect against the development of trilateral retinoblastoma [
         <a href="#rid67">
          67
         </a>
         ]. However, this is controversial, and the reduction in the rate of trilateral retinoblastoma observed in the chemoreduction era may also be related to the avoidance of radiation and its oncogenic effects in patients with heritable retinoblastoma. Other reports suggest chemotherapy (specifically
         <a class="drug drug_pediatric" data-topicid="13292" href="/z/d/drug information/13292.html" rel="external">
          etoposide
         </a>
         ) may predispose to the development of secondary acute myeloid leukemia later in life in patients with heritable retinoblastoma [
         <a href="#rid67">
          67-69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H39708418">
         <span class="h3">
          Cryotherapy and laser photocoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cryotherapy and/or laser photocoagulation can be used to treat smaller tumors (&lt;6 mm in diameter and &lt;3 mm thick) [
         <a href="#rid70">
          70,71
         </a>
         ] and may be used in conjunction with chemotherapy [
         <a href="#rid70">
          70-74
         </a>
         ]. If these local modalities are successful, the treated tumor usually regresses within six weeks, although it may take longer [
         <a href="#rid70">
          70,71
         </a>
         ]. Complications of these methods include transient serous retinal detachment, rhegmatogenous retinal detachment (particularly with cryotherapy), visually significant retinal vascular occlusion, vitreous hemorrhage, retinal traction, and preretinal fibrosis [
         <a href="#rid19">
          19,70,75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H192505144">
         <span class="h3">
          Radioactive plaques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radioactive plaque therapy (I-125 brachytherapy) involves securing a radioactive plaque to the sclera at the base of the tumor. The radiation dose is approximately 40 to 45 gray (Gy) delivered to the tumor apex.
        </p>
        <p>
         Based on retrospective data, plaque therapy achieves tumor control in approximately 80 percent of tumors and is most effective in small tumors without vitreous or subretinal seeding [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Limitations of plaque therapy include the following [
         <a href="#rid76">
          76-78
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plaque therapy is generally not effective as primary therapy for large tumors (ie, ≥15 mm in diameter or ≥8 mm thick), multifocal tumors, or tumors in the posterior one-half of the globe or if there is active seeding far from the main tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation complications (eg, cataract, radiation retinopathy, optic neuropathy) may occur in up to one-third of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The amount of radiation delivered to the optic nerve and fovea must be carefully considered, particularly if there is potential for preserved vision as this will be limited with radiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placement of plaques can be technically difficult, and a second surgical procedure is required for removal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depending on local radiation safety laws, children may have to be hospitalized for the duration of treatment. In the United States, many states have laws requiring individuals with implanted radioactive devices to stay in the hospital during their treatment due to the potential risk of public and environmental exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is a theoretical risk of developing radiation-induced secondary malignancies in patients with heritable retinoblastoma; however, this risk is very low if custom-designed plaques are used along with radiation shielding.
        </p>
        <p>
        </p>
        <p>
         Because of these limitations, other modalities (eg, cryotherapy and laser phototherapy for small tumors, local chemotherapy or systemic chemotherapy for larger tumors) are often preferred over plaque therapy for primary therapy. Radioactive plaque therapy is most commonly used as a secondary therapy, after local treatment failure.
        </p>
        <p class="headingAnchor" id="H2230881276">
         <span class="h3">
          Enucleation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enucleation usually is indicated for  (
         <a class="graphic graphic_table graphicRef78948" href="/z/d/graphic/78948.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid19">
          19,70,71
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unilateral disease in which there is a large tumor and limited to no visual potential
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blind, painful eyes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors that extend into the optic nerve
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For large recurrences after "globe-conserving" treatment wherein the visual prognosis is poor (secondary enucleation)
        </p>
        <p>
        </p>
        <p>
         Most unilateral group E and some unilateral group D eyes require enucleation. In addition, enucleation is often performed if the eye has secondary glaucoma, poor view to the fundus with presumed active tumor (eg, from vitreous hemorrhage), or anterior chamber invasion.
        </p>
        <p>
         Potential complications of enucleation include inadvertent scleral perforation with seeding of tumor cells into the orbit.
        </p>
        <p>
         Following enucleation, adjuvant systemic chemotherapy is provided (often combined with focal radiotherapy to the orbit) if there is a positive optic nerve margin or trans-scleral/extrascleral extension (which is, thankfully, a rare event) [
         <a href="#rid3">
          3,55
         </a>
         ]. Patients with these findings are at high risk for metastatic spread. Additional, more common factors associated with increased risk of metastatic disease include tumor extension beyond the lamina cribrosa, intrascleral invasion, and massive choroidal invasion [
         <a href="#rid55">
          55,56,79
         </a>
         ]. Practice varies regarding the use of adjuvant chemotherapy (without radiotherapy) in patients with these risk factors [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         An orbital implant (typically hydroxyapatite or porous polyethylene, although some surgeons prefer nonporous silicone implants) is placed at the time of enucleation. After the overlying conjunctiva has healed (approximately six weeks), a prosthesis can be fitted by an ocularist. Implant migration or exposure are known complications and increase during chemotherapy [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Children who undergo enucleation for retinoblastoma must be monitored closely for orbital relapse in the two years after surgery. In a cohort of 1674 consecutive patients undergoing enucleation between 1914 and 2006, the incidence of orbital recurrence was 4.2 percent [
         <a href="#rid81">
          81
         </a>
         ]. All recurrences were diagnosed within 24 months of enucleation and 97 percent within 12 months. Most patients (85 percent) with orbital recurrence also developed metastatic disease. Seventy-five percent of patients with orbital recurrence died from metastatic retinoblastoma. However, the mortality rate appears to be lower in patients diagnosed with orbital recurrence after 1984 (1 of 11 patients, 9 percent after 1984, compared with 75 percent for the entire cohort).
        </p>
        <p class="headingAnchor" id="H3756759032">
         <span class="h3">
          External beam radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         EBRT was the original globe-sparing treatment for retinoblastoma; however, in the contemporary era it is rarely utilized, except in certain salvage situations. Due to the delayed tumorigenic potential of radiotherapy in patients with retinoblastoma, intravenous chemotherapy, OAC, and focal therapies have replaced EBRT as the primary globe-conserving treatments for retinoblastoma [
         <a href="#rid57">
          57,72,73
         </a>
         ]. (See
         <a class="local">
          'Chemotherapy'
         </a>
         above and
         <a class="local">
          'Cryotherapy and laser photocoagulation'
         </a>
         above.)
        </p>
        <p>
         EBRT is a highly effective treatment modality for eyes with active retinoblastoma, but the risk of secondary cancers and local side effects limit its use to globe salvage after failure of other treatment modalities in children older than 12 to 18 months of age. The risk of tumor recurrence following EBRT in one series of 180 tumors was 7 percent, with all recurring within 40 months [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         The major complication of EBRT is induction of secondary malignancies [
         <a href="#rid77">
          77,83-87
         </a>
         ]. The importance of radiation-induced secondary malignancies is illustrated by the fact that in the United States, more patients with retinoblastoma die of second tumors than of the retinoblastoma itself [
         <a href="#rid83">
          83
         </a>
         ]. The increased risk of secondary tumors is seen primarily in patients with heritable retinoblastoma. In one report, the 30-year cumulative incidence of second cancers was markedly increased in the 137 patients treated with radiotherapy (35 percent, compared with 6 percent in the 78 who did not receive radiation) [
         <a href="#rid85">
          85
         </a>
         ]. Secondary malignancies occur most commonly in the field of radiation and the risk appears to be dose related [
         <a href="#rid88">
          88,89
         </a>
         ].
        </p>
        <p>
         Other radiation-related complications include radiation damage to the retina, optic nerve, lacrimal gland, and lens; loss of eyelashes [
         <a href="#rid90">
          90
         </a>
         ]; and midface hypoplasia with retardation of orbital bone growth when radiation is given before 12 months of age [
         <a href="#rid91">
          91-95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H860556421">
         <span class="h1">
          OUTCOME
         </span>
        </p>
        <p class="headingAnchor" id="H634369497">
         <span class="h2">
          Prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various clinical and histopathologic features influence prognosis in patients with retinoblastoma. Features associated with a poor prognosis include [
         <a href="#rid96">
          96
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delay in diagnosis of more than six months [
         <a href="#rid97">
          97-100
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extraocular disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presenting with orbital pseudocellulitis due to massive tumor necrosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intraocular pressure (IOP) at time of diagnosis, which correlates with high-risk histopathologic features [
         <a href="#rid101">
          101
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Massive choroidal, optic nerve, scleral, or orbital invasion, which increases the risk of metastatic disease [
         <a href="#rid97">
          97,102-105
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-grade tumor anaplasia [
         <a href="#rid105">
          105
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of external beam radiotherapy (EBRT), due to the risk of subsequent secondary cancers, as previously discussed (see
         <a class="local">
          'External beam radiation therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2778895556">
         <span class="h2">
          Survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinoblastoma survival varies geographically, ranging from &lt;30 percent in resource-limited settings to &gt;90 percent in resource-abundant settings [
         <a href="#rid106">
          106
         </a>
         ]. The overall five-year survival rate for children with retinoblastoma in the United States is &gt;95 percent [
         <a href="#rid107">
          107,108
         </a>
         ]. Patients who develop metastatic disease usually do so within one year of diagnosis; a child who remains recurrence free for five years after diagnosis is generally considered cured [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastatic disease
         </strong>
         – The prognosis for children with metastatic disease has historically been poor, particularly for relapses in the central nervous system [
         <a href="#rid110">
          110
         </a>
         ]. In most reports, 1-year to 18-month survival rates for patients with hematogenous metastases are approximately 50 percent [
         <a href="#rid110">
          110-114
         </a>
         ]. As previously discussed, several case series have reported improved survival with intensive multimodal therapy with autologous hematopoietic stem cell rescue [
         <a href="#rid14">
          14-18
         </a>
         ]. In a prospective multicenter trial from the Children's Oncology Group involving 57 children with metastatic retinoblastoma who were treated with intensive multimodal therapy, event-free survival at 36 months was 88 percent among patients with regional extraocular disease and 79 percent for patients with disseminated metastatic disease (excluding central nervous system disease) [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Metastatic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trilateral retinoblastoma
         </strong>
         – Survival for children with trilateral retinoblastoma (ie, intraocular retinoblastoma and concomitant intracranial tumor, usually in the pineal gland) has improved since the mid-1990s, when it was almost universally fatal [
         <a href="#rid115">
          115
         </a>
         ]. In a 2014 systematic review and meta-analysis of cases reported after 1994, five-year survival for patients with pineal trilateral retinoblastoma was 44 percent (95% CI 26-61 percent) and five-year survival for nonpineal trilateral retinoblastoma was 57 percent (95% CI 30-77) [
         <a href="#rid13">
          13
         </a>
         ]. As previously discussed, intensive chemotherapy regimens with autologous hematopoietic stem cell rescue has been associated with prolonged disease-free survival in small case series. (See
         <a class="local">
          'Intracranial tumor ("trilateral" retinoblastoma)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1749461074">
         <span class="h2">
          Vision
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis for vision in bilaterally affected children depends upon the extent of tumor involvement; the prognosis is better for tumors that are small, do not involve the fovea, and have limited retinal detachment and seeding [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         Among children with group A to D tumors successfully treated with chemoreduction, factors that predict preservation of visual acuity of 20/40 or better at five years after treatment include tumor location ≥3 mm from the foveola and optic disc and the absence of subretinal fluid [
         <a href="#rid117">
          117
         </a>
         ]. Predicting visual outcome is difficult with advanced disease; however, factors predictive of poor vision in group D eyes include involvement of &gt;50 percent of the macula, complete retinal detachment, and three or more quadrants of vitreous seeding at presentation [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         For children with unilateral disease, the prognosis for vision in the unaffected eye is excellent [
         <a href="#rid19">
          19
         </a>
         ]. The risk of developing tumors in the contralateral eye depends primarily on germline RB1 status. However, if the contralateral eye remains disease-free after three years, the risk is very low.
        </p>
        <p class="headingAnchor" id="H1157807156">
         <span class="h2">
          Second malignancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with heritable retinoblastoma (ie, a germline
         <em>
          RB1
         </em>
         gene mutation), the risk of developing a second nonocular malignancy is approximately 0.5 to 1 percent per year. Thus, the cumulative risk over 40 years is approximately 18 to 35 percent [
         <a href="#rid118">
          118,119
         </a>
         ]. In contrast, second malignancies are far less common in patients with nonheritable retinoblastoma, occurring in only 2 percent of cases in one large cohort [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         Patients with heritable retinoblastoma are at risk for developing PNET tumors, usually in the pineal gland (ie, trilateral retinoblastoma). In some patients, these tumors may be present at the time of diagnosis, whereas in others, the tumor may develop subsequent to initial diagnosis, typically before the age of five years. For this reason, many centers perform routine magnetic resonance imaging screening during the first three to five years of life in patients with heritable retinoblastoma [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="local">
          'Imaging'
         </a>
         below.)
        </p>
        <p>
         The risk of secondary malignancy appears to be greatest among patients treated with radiation therapy before the age of one year [
         <a href="#rid83">
          83
         </a>
         ]. In a meta-analysis of 676 second primary tumors reported in the literature between 1961 and 2006, the type of second primary tumors was related to age [
         <a href="#rid89">
          89
         </a>
         ]. The median age for PNET was 2.7 years; for sarcomas, 13 years; for melanomas, 27 years, and for carcinomas, 29 years.
        </p>
        <p>
         The most common second malignancies in survivors of retinoblastoma include osteogenic and soft tissue sarcomas [
         <a href="#rid88">
          88,119-124
         </a>
         ]. These tumors are presumed to be radiation-related, and the risk appears to correlate with the dose of radiation. Epithelial cancers (eg, melanoma, bladder, lung, breast) have also been reported [
         <a href="#rid84">
          84,88,118,119,122,123
         </a>
         ]. In the modern era, the use of radiation therapy in globe salvaging treatment for retinoblastoma is quite rare. (See
         <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">
          "Radiation-associated sarcomas", section on 'Genetic predisposition'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14261.html" rel="external">
          "Radiation-associated sarcomas", section on 'Childhood RT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1090352379">
         <span class="h2">
          Quality of life
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies reporting on quality of life (QoL) in survivors of retinoblastoma have reached variable conclusions [
         <a href="#rid125">
          125-129
         </a>
         ]. Most studies report that survivors have similar QoL compared with their peers [
         <a href="#rid126">
          126,127,129
         </a>
         ]. However, in some studies QoL scores were lower in retinoblastoma survivors compared with reference population, though the differences were generally small [
         <a href="#rid125">
          125,126
         </a>
         ]. Visually impaired survivors reported lower QoL compared with those with normal vision. Parents tended to rate the survivors' QoL lower than the survivors did themselves [
         <a href="#rid126">
          126,127,129
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2721783007">
         <span class="h1">
          LONG-TERM FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term follow-up for patients with retinoblastoma is best accomplished by multidisciplinary subspecialty teams. It includes monitoring for tumor recurrence and following for long-term treatment-related complications, as discussed in the following sections. Additional aspects of long-term follow-up are addressed in guidelines published by the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=107561" target="_blank">
          Children's Oncology Group
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2836245108">
         <span class="h2">
          Ophthalmologic follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk period for extraocular spread after successful treatment or enucleation is generally recognized to be 24 months with most occurring in the first 12 months [
         <a href="#rid81">
          81
         </a>
         ]. Ophthalmologic follow-up after treatment for retinoblastoma varies based upon the level and activity of disease; however, it is generally monthly during active treatment with a progressive increase in treatment interval. Once the child has remained disease free without treatment for an extended time (typically two years), the frequency of examinations can be decreased and the examinations can often be done in the office instead of under anesthesia, provided the child is cooperative with the examination.
        </p>
        <p>
         Children who have undergone enucleation may participate in sports as long as they use proper polycarbonate protective eyewear. The need for protective eyewear for all patients cannot be overemphasized. Participation in boxing is discouraged because protective eyewear is not permitted.
        </p>
        <p>
         Lifelong ophthalmologic follow-up is necessary for all survivors of childhood retinoblastoma because late complications may occur (eg, cataract, optic neuropathy, retinopathy, socket issues), particularly in patients treated with radiotherapy. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Effects on the eyes and optic pathways'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H742764882">
         <span class="h2">
          Imaging
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance for intracranial tumors
         </strong>
         – Many centers perform routine screening with brain magnetic resonance imaging (including images through the pineal region) every six months until age three to five in children with heritable retinoblastoma to screen for development of intracranial tumors (commonly called "trilateral" retinoblastoma) [
         <a href="#rid130">
          130
         </a>
         ]. The value of magnetic resonance imaging screening was evaluated in a meta-analysis that included individual data from 106 children with trilateral retinoblastoma [
         <a href="#rid69">
          69
         </a>
         ]. Intracranial tumors were detected through routine screening in 15 cases, whereas in 31 patients, screening was not performed and the intracranial tumor was detected based on symptoms (in the remaining 60 cases, trilateral retinoblastoma was either present at the time of initial diagnosis or it was unclear whether screening was performed). Compared with patients whose tumors were detected at a symptomatic stage, those who underwent screening had earlier detection of the intracranial tumor (1 versus 22 months) and smaller tumor size (20 versus 30 mm). Children who underwent screening survived longer (16 versus 8 months); however, the age at death was similar (36 versus 37 months). Cumulative five-year survival was 27 percent among children who underwent screening, whereas no child whose tumor was detected at a symptomatic stage survived beyond five years. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Intracranial tumors ("trilateral" retinoblastoma)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other imaging
         </strong>
         – Routine computed tomography scans and bone scans are generally
         <strong>
          not
         </strong>
         necessary. Imaging confers risks and burdens and has not been shown to improve outcomes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2716692335">
         <span class="h2">
          Second malignancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the risks associated with metastatic spread from the original tumor, survivors of retinoblastoma require lifetime follow-up because of their propensity to develop second nonocular primary malignancies. Patients should receive counseling on the importance of routine measures to reduce the likelihood of second malignancies, including refraining from smoking, using sunscreen, and avoiding exposure to other DNA-damaging agents [
         <a href="#rid84">
          84
         </a>
         ]. Long-term survivors should be followed for the development of late second malignancies with periodic physical examination, laboratory screening, and radiology testing, depending upon specific risk factors. (See
         <a class="local">
          'Second malignancies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2298253217">
         <span class="h2">
          Hearing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who receive systemic intravenous
         <a class="drug drug_pediatric" data-topicid="13117" href="/z/d/drug information/13117.html" rel="external">
          carboplatin
         </a>
         are at risk for hearing loss and require long-term audiologic follow-up. The risk may be higher when chemotherapy is given to infants &lt;6 months old [
         <a href="#rid131">
          131,132
         </a>
         ]. In a long-term follow-up study, 3 percent of adult survivors of childhood retinoblastoma developed severe hearing loss [
         <a href="#rid124">
          124
         </a>
         ]. An ongoing clinical trial is evaluating the risk of hearing loss in patients treated with intra-arterial carboplatin (ie, ophthalmic artery chemosurgery [OAC]) [
         <a href="#rid133">
          133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy", section on 'Carboplatin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2835323074">
         <span class="h2">
          Endocrinopathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine dysfunction (eg, hypothalamic and pituitary endocrinopathies, hypothyroidism) may occur in patients treated with radiotherapy. Systemic chemotherapy can reduce ovarian function and spermatogenesis; however, these effects are usually temporary [
         <a href="#rid134">
          134
         </a>
         ]. In a small study, ovarian function was not affected after OAC [
         <a href="#rid135">
          135
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">
          "Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2048024765">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary approach
         </strong>
         – Retinoblastoma typically presents as leukocoria  (
         <a class="graphic graphic_picture graphicRef56724" href="/z/d/graphic/56724.html" rel="external">
          picture 1
         </a>
         ) or strabismus (crossing of the eyes) in a child under the age of two years. Untreated retinoblastoma is a deadly disease. Prompt referral to an ophthalmologist and appropriate management by a multidisciplinary team are necessary to optimize visual outcome and survival. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Multidisciplinary approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment goals
         </strong>
         – Treatment of retinoblastoma is aimed at achieving the following goals (see
         <a class="local">
          'Goals'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Eradication of the disease to prevent mortality
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Salvage of the globe, if done without risk to the child's life
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preservation of vision to the greatest extent possible
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prevention of late sequelae, particularly subsequent neoplasms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment approach
         </strong>
         – A variety of treatment options are available for children with retinoblastoma, including several globe- and vision-sparing therapies. First-line therapeutic options include ophthalmic artery chemosurgery (OAC), systemic chemotherapy, radioactive plaques (I-125 brachytherapy), and enucleation. Adjunctive salvage therapies include cryotherapy, laser photoablation, and intravitreal injection of chemotherapy. In the contemporary era, external beam radiation therapy (EBRT) is rarely used, except in certain salvage situations. (See
         <a class="local">
          'Treatment modalities for intraocular disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of initial treatment is based upon  (
         <a class="graphic graphic_algorithm graphicRef108702" href="/z/d/graphic/108702.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Treatment approach'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumor size, location, and laterality
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence or absence of vitreous or subretinal seeds
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient age
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Visual prognosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Survival
         </strong>
         – The overall five-year survival rate for children with retinoblastoma in the United States is &gt;95 percent. Patients who develop metastatic disease usually do so within one year of diagnosis; a child who remains recurrence free for five years after diagnosis is considered cured. (See
         <a class="local">
          'Survival'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vision
         </strong>
         – The prognosis for vision in bilaterally affected children depends upon the extent of tumor involvement; the prognosis is better for tumors that are small, do not involve the fovea, and have limited retinal detachment and seeding. (See
         <a class="local">
          'Vision'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk of secondary malignancies
         </strong>
         – Survivors of heritable retinoblastoma have a lifelong increased risk of second nonocular malignancy, most commonly osteogenic and soft tissue sarcomas. The risk of secondary malignancy is greatest among patients treated with radiation therapy before the age of one year. (See
         <a class="local">
          'Second malignancies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term follow-up
         </strong>
         – Long-term follow-up for patients with retinoblastoma includes monitoring for tumor recurrence and following for long-term treatment-related complications. The risk period for extraocular spread after successful treatment or enucleation is 12 to 24 months. In addition to routine ophthalmologic follow-up, many centers perform screening with brain magnetic resonance imaging (including images through the pineal region) every six months until age three to five in children with heritable retinoblastoma to screen for development of a midline primitive neuroectodermal tumors. (See
         <a class="local">
          'Long-term follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2640902238">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Ronald Teed, MD, Paul L Kaufman, MD, and Jonathan Kim, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2012 (Accessed on March 30, 2016).
         </li>
         <li class="breakAll">
          Retinoblastoma Treatment in PDQ Cancer Information Summaries, available at: http://www.ncbi.nlm.nih.gov/books/NBK66006 (Accessed on March 31, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of Retinoblastoma in 2015: Agreement and Disagreement. JAMA Ophthalmol 2015; 133:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH. Retinoblastoma: saving life with vision. Annu Rev Med 2014; 65:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol 2016; 31:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005; 18:41.
          </a>
         </li>
         <li class="breakAll">
          AJCC Cancer Staging Manual, 8th ed, Amin MB, Edge S, Greene F, et al (Eds), Springer, 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Marr BP, Francis JH, et al. Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy). PLoS One 2016; 11:e0156806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holladay DA, Holladay A, Montebello JF, Redmond KP. Clinical presentation, treatment, and outcome of trilateral retinoblastoma. Cancer 1991; 67:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik RK, Friedman HS, Djang WT, et al. Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide. Am J Ophthalmol 1986; 102:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkel IJ, Jubran RF, Gururangan S, et al. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer 2010; 54:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jubran RF, Erdreich-Epstein A, Butturini A, et al. Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol 2004; 26:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong MC, Kors WA, de Graaf P, et al. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 2014; 15:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kremens B, Wieland R, Reinhard H, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 2003; 31:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkel IJ, Chan HS, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer 2010; 55:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkel IJ, Khakoo Y, Kernan NA, et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 2010; 55:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caselli D, Tamburini A, La Torre A, et al. High-dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: report of five cases. Pediatr Transplant 2014; 18:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkel IJ, Krailo MD, Chantada GL, et al. Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321). J Clin Oncol 2017; 35:10506.
          </a>
         </li>
         <li class="breakAll">
          Hurwitz RL, Shields CL, Shields JA, et al.. Retinoblastoma. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.809.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Daniels AB, Marr BP, et al. Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. PLoS One 2016; 11:e0146582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Ottaviani D, Sefta M, et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nat Commun 2021; 12:5578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li HT, Xu L, Weisenberger DJ, et al. Characterizing DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy. Nat Commun 2022; 13:5523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stålhammar G, Yeung A, Mendoza P, et al. Gain of Chromosome 6p Correlates with Severe Anaplasia, Cellular Hyperchromasia, and Extraocular Spread of Retinoblastoma. Ophthalmol Sci 2022; 2:100089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003; 21:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chantada GL, Fandiño AC, Casak SJ, et al. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004; 25:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 2012; 118:5663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 2011; 129:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour P, Chalouhi N, Tjoumakaris S, et al. Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr 2012; 10:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011; 129:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 2014; 121:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yannuzzi NA, Francis JH, Marr BP, et al. Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis. JAMA Ophthalmol 2015; 133:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palioura S, Gobin YP, Brodie SE, et al. Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (&gt;50%) retinal detachment. Pediatr Blood Cancer 2012; 59:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis JH, Abramson DH, Gobin YP, et al. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Ophthalmology 2015; 122:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyse E, Handa JT, Friedman AD, Pearl MS. A review of the literature for intra-arterial chemotherapy used to treat retinoblastoma. Pediatr Radiol 2016; 46:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marasligiller SA, Williams BK, Vadivelu S, et al. Ocular survival after intra-arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution. Pediatr Blood Cancer 2023; 70:e30071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousef YA, Soliman SE, Astudillo PP, et al. Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review. JAMA Ophthalmol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson EC, Elhammady MS, Quintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 2011; 114:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 2011; 129:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eagle RC Jr, Shields CL, Bianciotto C, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2011; 129:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munier FL, Beck-Popovic M, Balmer A, et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina 2011; 31:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vijayakrishnan R, Shields CL, Ramasubramanian A, et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol 2010; 128:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips TJ, McGuirk SP, Chahal HK, et al. Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma. Paediatr Anaesth 2013; 23:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris EA. Letter to the Editor regarding 'Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma' by Phillips, McGuirk, Chahal, et al. Paediatr Anaesth 2014; 24:229.
          </a>
         </li>
         <li class="breakAll">
          Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma, study details available at: https://clinicaltrials.gov/ct2/show/NCT02097134 (Accessed on March 26, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           De la Huerta I, Seider MI, Hetts SW, Damato BE. Delayed Cerebral Infarction Following Intra-arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol 2016; 134:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol 2013; 97:1231.
          </a>
         </li>
         <li class="breakAll">
          Children's Oncology Group: A Study to Give Treatment Inside the Eye to Treat Retinoblastoma. Study record detail. Available at: https://clinicaltrials.gov/ct2/show/NCT05504291 (Accessed on November 30, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999; 106:1947.
          </a>
         </li>
         <li class="breakAll">
          Study of treatment for patients with cancer of the eye - retinoblastoma https://clinicaltrials.gov/ct2/show/results/NCT00186888 (Accessed on January 06, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manjandavida FP, Honavar SG, Reddy VA, Khanna R. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology 2014; 121:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JW, Yau JW, Moshfeghi D, Fishman M. Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular carboplatin. J Pediatr Ophthalmol Strabismus 2010; 47 Online:e1.
          </a>
         </li>
         <li class="breakAll">
          Protocol for the study and treatment of participants with intraocular retinoblastoma https://clinicaltrials.gov/ct2/show/NCT01783535 (Accessed on January 06, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002; 120:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chantada G, Fandiño A, Dávila MT, et al. Results of a prospective study for the treatment of retinoblastoma. Cancer 2004; 100:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien JM, Smith BJ. Chemotherapy in the treatment of retinoblastoma. Int Ophthalmol Clin 1996; 36:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Mashayekhi A, Demirci H, et al. Practical approach to management of retinoblastoma. Arch Ophthalmol 2004; 122:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002; 120:1653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 2004; 138:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009; 116:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schouten-Van Meeteren AY, Moll AC, Imhof SM, Veerman AJ. Overview: chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol 2002; 38:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113:2276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer 2013; 60:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001; 119:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007; 114:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999; 17:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999; 36:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uusitalo M, Wheeler S, O'Brien JM. New approaches in the clinical management of retinoblastoma. Ophthalmol Clin 1999; 12:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997; 104:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumal CR, Shields CL, Shields JA, Tasman WS. Surgical repair of rhegmatogenous retinal detachment after treatment for retinoblastoma. Ophthalmology 1998; 105:2134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 2001; 108:2116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohney BG, Robertson DM, Schomberg PJ, Hodge DO. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 1998; 126:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address:
           <span class="__cf_email__" data-cfemail="82f2e3f7eee4ebece5e7f0c2e7fbe7e1e3ece1e7f0ace1edef">
            [email protected]
           </span>
           , ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011; 129:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang P, Kim JW, McGovern K, et al. Porous orbital implant after enucleation in retinoblastoma patients: indications and complications. Orbit 2018; 37:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JW, Kathpalia V, Dunkel IJ, et al. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 2009; 93:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AD, Garway-Heath D, Love S, et al. Relationship of regression pattern to recurrence in retinoblastoma. Br J Ophthalmol 1993; 77:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 1998; 105:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontanesi J, Parham DM, Pratt C, Meyer D. Second malignant neoplasms in children with retinoblastoma: the St. Jude Children's Research Hospital experience. Ophthalmic Genet 1995; 16:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araki Y, Matsuyama Y, Kobayashi Y, et al. Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan. Jpn J Clin Oncol 2011; 41:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo KI, Harbour JW. Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. Arch Ophthalmol 2010; 128:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks HL Jr, Meyer D, Shields JA, et al. Removal of radiation-induced cataracts in patients treated for retinoblastoma. Arch Ophthalmol 1990; 108:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol 1997; 15:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameniya T, Matsumura M, Hirose Y. Effects of radiation after enucleation without implantation on orbital development of patients with retinoblastoma. Ophthalmologica 1977; 174:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denys D, Kaste SC, Kun LE, et al. The effects of radiation on craniofacial skeletal growth: a quantitative study. Int J Pediatr Otorhinolaryngol 1998; 45:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peylan-Ramu N, Bin-Nun A, Skleir-Levy M, et al. Orbital growth retardation in retinoblastoma survivors: work in progress. Med Pediatr Oncol 2001; 37:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imhof SM, Mourits MP, Hofman P, et al. Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology 1996; 103:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus 2000; 37:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messmer EP, Heinrich T, Höpping W, et al. Risk factors for metastases in patients with retinoblastoma. Ophthalmology 1991; 98:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol 1999; 83:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erwenne CM, Franco EL. Age and lateness of referral as determinants of extra-ocular retinoblastoma. Ophthalmic Paediatr Genet 1989; 10:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaliki S, Srinivasan V, Gupta A, et al. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology 2015; 122:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim ME, Shah S, Zolfaghari E, et al. An Intraocular Pressure Predictive of High-risk Histopathologic Features in Group E Retinoblastoma Eyes. Int Ophthalmol Clin 2019; 59:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol 2002; 47:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994; 73:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993; 77:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza PR, Specht CS, Hubbard GB, et al. Histopathologic grading of anaplasia in retinoblastoma. Am J Ophthalmol 2015; 159:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet 2012; 379:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009; 93:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamboli D, Topham A, Singh N, Singh AD. Retinoblastoma: A SEER Dataset Evaluation for Treatment Patterns, Survival, and Second Malignant Neoplasms. Am J Ophthalmol 2015; 160:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology 1987; 94:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Ellsworth RM, Grumbach N, et al. Retinoblastoma: correlation between age at diagnosis and survival. J Pediatr Ophthalmol Strabismus 1986; 23:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schvartzman E, Chantada G, Fandiño A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol 1996; 14:1532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratt CB, Fontanesi J, Chenaille P, et al. Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol 1994; 11:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chantada G, Fandiño A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 2003; 40:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 1995; 13:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blach LE, McCormick B, Abramson DH, Ellsworth RM. Trilateral retinoblastoma--incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys 1994; 29:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JL, Jubran R, Wong K, et al. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience. Br J Ophthalmol 2014; 98:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 2005; 123:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008; 100:1771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacCarthy A, Bayne AM, Brownbill PA, et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 2013; 108:2455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 2001; 108:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23:2272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DN, Chou JF, Oeffinger KC, et al. Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study. Cancer 2016; 122:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk J, Imhof SM, Moll AC, et al. Quality of life of adult retinoblastoma survivors in the Netherlands. Health Qual Life Outcomes 2007; 5:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belson PJ, Eastwood JA, Brecht ML, et al. A Review of Literature on Health-Related Quality of Life of Retinoblastoma Survivors. J Pediatr Oncol Nurs 2020; 37:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk J, Huisman J, Moll AC, et al. Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands. Health Qual Life Outcomes 2007; 5:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DN, Chou JF, Francis JH, et al. Vision-Targeted Health-Related Quality of Life in Adult Survivors of Retinoblastoma. JAMA Ophthalmol 2018; 136:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morse M, Parris K, Qaddoumi I, et al. Psychosocial outcomes and quality of life among school-age survivors of retinoblastoma. Pediatr Blood Cancer 2023; 70:e29983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagley LJ, Hurst RW, Zimmerman RA, et al. Imaging in the trilateral retinoblastoma syndrome. Neuroradiology 1996; 38:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30:1034.
          </a>
         </li>
         <li class="breakAll">
          Memorial Sloan Kettering Cancer Center. Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children. Study record details. Available at: https://clinicaltrials.gov/ct2/show/NCT03866460 (Accessed on December 15, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroud JS, Mutch D, Rader J, et al. Effects of cancer treatment on ovarian function. Fertil Steril 2009; 92:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marathe PH, Dunkel IJ, Francis JH, et al. Biochemical measures of ovarian function in female survivors of retinoblastoma treated with intra-arterial melphalan: an initial report. Ophthalmic Genet 2022; 43:806.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 107561 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://seer.cancer.gov/csr/1975_2012" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2012 (Accessed on March 30, 2016).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://www.ncbi.nlm.nih.gov/books/NBK66006" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Retinoblastoma Treatment in PDQ Cancer Information Summaries, available at: http://www.ncbi.nlm.nih.gov/books/NBK66006 (Accessed on March 31, 2016).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26378747" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Treatment of Retinoblastoma in 2015: Agreement and Disagreement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24422571" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Retinoblastoma: saving life with vision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26023180" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763190" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intraocular retinoblastoma: the case for a new group classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763190" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Intraocular retinoblastoma: the case for a new group classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27258771" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1985763" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical presentation, treatment, and outcome of trilateral retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3777087" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19908299" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Trilateral retinoblastoma: potentially curable with intensive chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14707710" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25126964" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Trilateral retinoblastoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12621463" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20486181" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20486171" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25039687" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : High-dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: report of five cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26756643" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34552068" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36130950" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Characterizing DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36246172" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Gain of Chromosome 6p Correlates with Severe Anaplasia, Cellular Hyperchromasia, and Extraocular Spread of Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743157" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of intraocular retinoblastoma with vincristine and carboplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15255113" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Activity of topotecan in retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516936" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22084221" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Chemosurgery for retinoblastoma: what we know after 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22793160" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15108036" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21320950" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24656794" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26181236" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22492689" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (&gt;50%) retinal detachment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25616769" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26886915" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A review of the literature for intra-arterial chemotherapy used to treat retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36349521" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Ocular survival after intra-arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26986443" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21294621" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21670326" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21746972" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Histopathologic observations after intra-arterial chemotherapy for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21273941" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21060044" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23668238" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24387155" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Letter to the Editor regarding 'Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma' by Phillips, McGuirk, Chahal, et al.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24387155" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Letter to the Editor regarding 'Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma' by Phillips, McGuirk, Chahal, et al.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27077487" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Delayed Cerebral Infarction Following Intra-arterial Chemotherapy for Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23740960" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23740960" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10519590" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10519590" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16794434" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Basic understanding of current classification and management of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24572675" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Management and outcome of retinoblastoma with vitreous seeds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21214147" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular carboplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21214147" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular carboplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12096963" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Postenucleation adjuvant therapy in high-risk retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14770442" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Results of a prospective study for the treatment of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8950630" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Chemotherapy in the treatment of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15136321" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Practical approach to management of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12470138" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Chemoreduction for unilateral retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10623688" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364213" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8906024" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19157557" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11984806" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Overview: chemotherapy for retinoblastoma: an expanding area of clinical research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16996605" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The International Classification of Retinoblastoma predicts chemoreduction success.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22997170" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11545631" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17613328" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561222" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9972509" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Recent developments in the management of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : New approaches in the clinical management of retinoblastoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8906025" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Chemotherapy plus local treatment in the management of intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400771" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8906022" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9818618" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Surgical repair of rhegmatogenous retinal detachment after treatment for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11713089" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727521" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24373763" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22084213" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29461921" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Porous orbital implant after enucleation in retinoblastoma patients: indications and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757474" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Orbital recurrence of retinoblastoma following enucleation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435390" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Relationship of regression pattern to recurrence in retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9544627" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14996857" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Lifetime risks of common cancers among retinoblastoma survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3211467" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Incidence of second neoplasms in patients with bilateral retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8556278" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Second malignant neoplasms in children with retinoblastoma: the St. Jude Children's Research Hospital experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21051531" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9333268" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20625047" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2256840" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Removal of radiation-induced cataracts in patients treated for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9060562" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Orbital development in long-term survivors of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/857221" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Effects of radiation after enucleation without implantation on orbital development of patients with retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9804014" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The effects of radiation on craniofacial skeletal growth: a quantitative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745876" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Orbital growth retardation in retinoblastoma survivors: work in progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594512" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845413" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Prognostic factors in retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2008269" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Risk factors for metastases in patients with retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10574806" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Delay in diagnosis of retinoblastoma: risk factors and treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2587030" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Age and lateness of referral as determinants of extra-ocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25841975" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30908281" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : An Intraocular Pressure Predictive of High-risk Histopathologic Features in Group E Retinoblastoma Eyes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11801265" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Risk factors for metastasis in retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8299091" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8218048" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25528954" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Histopathologic grading of anaplasia in retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22414599" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18718969" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Survival with retinoblastoma in the USA: 1975-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26255575" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Retinoblastoma: A SEER Dataset Evaluation for Treatment Patterns, Survival, and Second Malignant Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3587919" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3746592" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Retinoblastoma: correlation between age at diagnosis and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622068" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Results of a stage-based protocol for the treatment of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8060814" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Chemotherapy for extraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12518344" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Treatment of overt extraocular retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7707117" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Etoposide and carboplatin in extraocular retinoblastoma: a study by the SociétéFrançaise d'Oncologie Pédiatrique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8040018" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Trilateral retinoblastoma--incidence and outcome: a decade of experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24671926" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286614" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Long-term visual outcome following chemoreduction for retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19066271" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23674091" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8320741" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Mortality from second tumors among long-term survivors of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11581064" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17202110" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15800318" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26755259" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17547767" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Quality of life of adult retinoblastoma survivors in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31762375" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : A Review of Literature on Health-Related Quality of Life of Retinoblastoma Survivors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18053178" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29710339" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Vision-Targeted Health-Related Quality of Life in Adult Survivors of Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36385462" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Psychosocial outcomes and quality of life among school-age survivors of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8692433" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Imaging in the trilateral retinoblastoma syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19148943" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370329" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Carboplatin-associated ototoxicity in children with retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370329" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Carboplatin-associated ototoxicity in children with retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18774559" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Effects of cancer treatment on ovarian function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36695494" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Biochemical measures of ovarian function in female survivors of retinoblastoma treated with intra-arterial melphalan: an initial report.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
